Despite several improvements in outcomes, metastatic prostate cancer remains deadly. Alterations in the homologous recombination repair (HRR) pathway are associated with more aggressive disease. Olaparib and rucaparib, two poly-ADP-ribose polymerase (PARP) inhibitors, have received approval from the authorities of several countries for their anti-tumoral effects in patients with metastatic castration-resistant prostate cancers harboring HRR gene alterations, in particular BRCA2. More recently, it has been hypothesized that new hormonal therapies (NHTs) and PARP inhibitors (PARPi) could have synergistic actions and act independently of HRR deficiency. This review proposes to discuss the advantages and disadvantages of PARPi used as monotherapy or in combination with NHTs and whether there is a need for molecular selection.
Therapeutic advances in medical oncology. 2024 May 31*** epublish ***
Diego Teyssonneau, Charles Dariane, Eric Barret, Jean-Baptiste Beauval, Laurent Brureau, Gaëlle Fiard, Gaëlle Fromont, Gilles Créhange, Mathieu Gauthé, Alain Ruffion, Raphaële Renard-Penna, Romain Mathieu, Paul Sargos, Morgan Rouprêt, Guillaume Ploussard, Guilhem Roubaud
Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, Bordeaux 33000, France., Department of Urology, Hôpital Européen Georges-Pompidou, APHP, Paris University, U1151 Inserm-INEM, Necker, Paris, France., Department of Urology, Institut Mutualiste Montsouris, Paris, France., Department of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, France., Department of Urology, CHU de Pointe-à-Pitre, University of Antilles, University of Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Pointe-à-Pitre, France., Department of Urology, Grenoble Alpes University Hospital, Université Grenoble Alpes, CNRS, Grenoble INP, TIMC-IMAG, Grenoble, France., Department of Pathology, CHRU Tours, Tours, France., Department of Radiation Oncology Curie Institute, Paris, France., Department of Nuclear Medicine, Scintep, Grenoble, France., Service d'Urologie Centre Hospitalier Lyon Sud, Hospices Civils de Lyon., AP-HP, Radiology, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France., Department of Urology, University of Rennes, Rennes, France., Department of Radiotherapy, Institut Bergonié, Bordeaux, Aquitaine, France., AP-HP, Urology, GRC 5 Predictive Onco-Uro, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France., Department of Medical Oncology, Institut Bergonié, Bordeaux, Aquitaine, France.